OncoSec Medical designs, develops, and commercializes DNA-based therapeutics to stimulate the immune system and treat cancer. Its lead product candidate, ImmunoPulse IL-12, uses electroporation to deliver a DNA-encoded interleukin-12 to reverse immunosuppression and destroy tumors. The company has partnerships with Merck & Co., Duke University, and Roswell Park Comprehensive Cancer Center to develop and evaluate its technologies.